Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
900 participants
OBSERVATIONAL
2024-03-15
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Clinical research on solid tumors has shown a reduction in the incidence of bone events with these treatments. Given this demonstrated effectiveness, it is important to optimize patient management by studying the characteristics of treated versus untreated patients, the incidence of bone events, and the impact of these events on patients.
A first nationwide study using EGB data (1/97th of the population) showed a low rate of management with bone-targeted treatment. Only 9% of patients with BM or a bone event associated with a cancer diagnosis received bone-targeted treatment. To validate and refine these results, we aim to replicate the protocol at Lyon Sud Hospital. Indeed, a greater amount of information will be available to answer the research question, and a number of biases can be avoided.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bone metatases
This study involves adults with bone metastases or who have had a bone event associated with a cancer diagnosis.
Study of the treatment
Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Study of the treatment
Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* And/or patients having had a skeletal event (pathological fracture; spinal cord compression; malignant hypercalcemia; bone pain and preventive orthopedic surgery or spine surgery) associated with a diagnosis of oncological pathology
* Adult patients
* No opposition
Exclusion Criteria
* Patients with a Long-Term Illiness (LTI) associated with a hospital diagnosis of Kaposi sarcoma over the same period as LTI
* Patient with a diagnosis of pathological fracture linked to a diagnosis of osteoporosis (M80)
* Patient under guardianship or curatorship
* Minor patients
* Patients not affiliated to the social security system at least 3 years before the diagnosis of MO and during the follow-up period.
* Patient already diagnosed with known bone metastases in the previous year.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brest University Hospital
Brest, France, France
Lyon Sud hospital, Hospices Civils de Lyon
Lyon, France, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL24_0905
Identifier Type: -
Identifier Source: org_study_id